infections are emerging, but their clinical significance remains unclear. Our objective was to compare patients who had hVISA bacteremia with patients who had methicillin-resistant S. aureus (MRSA) bacteremia.
Staphylococcus aureus is one of the commonest causes of bacteremia, skin and soft-tissue infections, and pneumonia worldwide [1] . Data recently published by The Surveillance Network-USA demonstrate that S. aureus is the most prevalent species isolated from inpatient specimens (18.7% of all bacterial isolates) and that 59% of such isolates from non-intensive care unit (ICU) patients were resistant to methicillin (MRSA) [2] .
Vancomycin has remained for many years the primary antibiotic for treating MRSA infections [3] . Despite the increasing use of vancomycin, the first report of MRSA with reduced susceptibility to vancomycin appeared as late as 1997 [4] , and since then only 7 cases of vancomycin-resistant S. aureus (VRSA), due to presence of the vanA gene complex, have been described [4, 5] . In recent years, several dozen S. aureus strains with intermediate resistance to vancomycin (VISA) were identified. Typically, these VISA strains have a slower growth rate, thickened cell wall, and reduced levels of penicillinbinding protein 4. The underlying genetic and biochemical mechanisms by which this reduced susceptibility to vancomycin occurs are not known [3, 6, 7] .
Among S. aureus, heterogeneous intermediate resistance to vancomycin seems to be the stage that precedes the development of intermediate resistance to this agent [8] . The vancomycin minimum inhibitory concentration (MIC) among heterogenous vancomycin-intermediate S. aureus (hVISA) isolates is within the susceptible range, but sub-populations of VISA are present at proportions ranging from 1 per 10 5 to 1 per 10 6 organisms [7, 8] . In recent studies, the rate of heterogenous intermediate resistance to vancomycin among MRSA isolates was reported to be 6%-11% [9, 10] .
The clinical significance of hVISA infections is obscure. In several uncontrolled studies, patients with hVISA infection had a complicated clinical course and high rates of infectionattributable mortality [10 -12] . The only study that compared hVISA bacteremia to MRSA bacteremia found that patients with hVISA bacteremia were more likely to have prolonged bacteremia and no response to vancomycin. No significant difference in mortality between the 2 groups was noted. However, only 5 patients with hVISA bacteremia were included in this study [13] .
The objective of our work was to compare patients who had hVISA bacteremia with patients who had MRSA bacteremia and to assess differences between these bacteremias with respect to the clinical course of disease and infection-related mortality. Laboratory methods. Resistance to methicillin was identified by the cefoxitin disk diffusion method [14] . All isolates included in the study were assessed for the presence of hVISA resistance by the Etest macromethod, as previously described [15] . Antibiotic susceptibility tests were performed on fresh samples because reversion of resistance after laboratory manipulation had been reported [16] . Criteria for defining hVISA were vancomycin and teicoplanin MICs of 8 g/mL or a teicoplanin MIC of 12 g/mL. Laboratory workers were blinded to patients' clinical characteristics. The ratio of hVISA bloodstream infections to MRSA bloodstream infections did not change during the study period (2003) (2004) (2005) (2006) .
PATIENTS, MATERIALS, AND METHODS

Case
Antibiotic susceptibility testing to all other antibiotics was performed by disk diffusion according to Clinical and Laboratory Standards Institute guidelines [14] . Vancomycin levels were measured at the discretion of treating physicians in the various hospital wards.
Clinical data. The medical records of all patients were reviewed, and data were retrieved by a questionnaire that summarized demographic and clinical characteristics as well as functional capacity. Comorbidity before the bacteremia was assessed by the Charlson comorbidity index [17] , demonstrated to be a good predictor of mortality in patients with S. aureus bacteremia [18] . Additional variables related to comorbidity were also recorded, including presence of artificial heart valves, pacemakers, orthopedic implants, organ transplantation, and hemodialysis, as well as receipt of chemotherapy or steroids 1 month and vancomycin 6 months before bacteremia onset.
We also recorded admission to the ICU, use of mechanical ventilation, presence of urinary catheter or central intravenous line, and presence of pneumonia or surgical site infection. Data were also collected on antibiotic treatment (the standard vancomycin regimen at the Sheba Medical Center is 1 g twice daily), trough vancomycin levels, presence of endocarditis (echocardiography is performed routinely for all patients with S. aureus bacteremia), osteomyelitis, concomitant bacteremia with other pathogens, duration of bacteremia, frequency of blood collection for culture 14 days after bacteremia onset, length of hospital stay, and mortality.
Death was attributed to infection if it occurred in the context of septic shock of endocarditis or if the patient had signs of infection and persistent positive blood cultures with no other plausible explanation for death.
Statistical analysis. All information retrieved from patients' charts and the laboratory were abstracted in a tabular manner, using Microsoft Access. Statistical analysis was performed using SAS software. The Student t test, the Pearson 2 test, and the Fisher exact test were used for comparisons, as appropriate, with the level of significance set at a P value of Ͻ.05.
Several multivariable logistic analyses were performed. Independent variables with a P value of Ͻ.1 were eligible for inclusion in models; a P value of Ͻ.05 indicated that variables were statistically significant. Ninety-five percent confidence intervals (95% CIs) were calculated. In the first regression analysis, the dependent variable was infection-attributable mortality, and the independent variables were age, sex, Charlson comorbidity index, functional capacity, presence of a urinary catheter in the past month, and osteomyelitis. A value indicating the presence or absence of a hVISA isolate was forced into the model. In the second regression analysis, the dependent variable was the presence of hVISA bacteremia, and the initial independent variables were presence of prosthesis, surgical site infection 1 month before bacteremia onset, endocarditis, osteomyelitis, duration of bacteremia, and development of resistance to rifampin.
RESULTS
The study included 27 patients with hVISA bacteremia and 223 patients with MRSA bacteremia. Patients with hVISA bacteremia were not significantly different from those with MRSA bacteremia in terms of age, sex, comorbidities, and being bedridden (table 1) . No significant differences were noted between the groups with regard to hospitalization or ICU stay 1 month before bacteremia onset. The rates of mechanical ventilation and nosocomial pneumonia were the same in both groups. Patients with hVISA bacteremia had significantly more prosthetic devices (i.e., artificial valves, pacemakers, and orthopedic implants) and more surgical site infections 1 month before bacteremia onset than patients with MRSA bacteremia. Exposure to vancomycin 6 months before bacteremia onset was not significantly different between patients with hVISA and those with MRSA bacteremia.
During the first 2 weeks after identification of S. aureus bacteremia, blood was obtained for culture at mean intervals (ϮSD) of 2.5 Ϯ 1.26 days from patients with hVISA and 2.9 Ϯ 2.30 days from patients with MRSA (P ϭ .18). A second blood sample for culture was not obtained during this period from 2 patients (7.4%) with hVISA who died 120 h after bacteremia onset or from 43 patients with MRSA, 17 (7.6%) of whom died 120 h after bacteremia onset.
Overall mortality was similar among patients with hVISA and those with MRSA (51% and 46%, respectively; P ϭ .6), as was infection-attributable mortality (44% and 36%, respectively; P ϭ .4) ( Vancomycin levels were measured according to the treating physicians' initiative in 152 patients (60%), of whom 22 (81%) were in the hVISA group and 129 (58%) were in the MRSA group (P ϭ .01). The mean trough vancomycin levels during the first week of bacteremia are presented in figure 1 . There was no significant difference in the distribution of vancomycin levels between patients with hVISA and those with MRSA, although vancomycin levels tended to be higher among patients with hVISA. There was also no significant correlation between trough vancomycin levels and infection-attributable mortality (figure 2) or length of bacteremia in both patient groups. Treatment with rifampin was a risk factor but not a prerequisite for developing rifampin resistance. Rifampin was added to vancomycin in 38 patients (16%), of whom 6 (22%) were in the hVISA group and 32 (14%) were in the MRSA group (P ϭ .3). Rifampin resistance was detected in isolates from 24 patients (10%), of whom 9 (38%) were treated with rifampin (P ϭ .002). Rifampin resistance developed significantly more frequently in the hVISA group than in the MRSA group (11 [44%] vs. 13 [5.9%] ; P Ͻ .001). In the subgroup of patients in whom rifampin resistance was detected, the duration of bacteremia was significantly longer for those with hVISA than for those with MRSA (12 days [range, 5-76 days] vs. 6 days [range, 1-60 days]; P Ͻ .001).
All patients with hVISA and MRSA bacteremia received vancomycin as first-line therapy. Among patients with hVISA bacteremia, 12 received vancomycin only. Ten patients concomitantly received rifampin and/or aminoglycosides. Eleven patients with persistent bacteremia were treated with additional antibiotics, all of which were added to vancomycin late in the course of bacteremia. Trimethoprim-sulfamethoxazole was prescribed for 8 patients, of whom 5 died from infection; fusidic acid was prescribed for 5 patients, of whom 2 died from infection; daptomycin was prescribed to 3 patients, of whom 2 died from infection, and quinupristindalfopristin was prescribed to 1 patient, who died from infection. For patients with MRSA, rifampin and/or aminoglycosides were prescribed if a prosthetic device or implant was present.
DISCUSSION
We found hVISA bacteremia to be significantly prolonged and associated with increased rates of endocarditis and osteomyelitis, compared with MRSA bacteremia. These higher rates of complications could be related to significantly different baseline features of patients with hVISA bacteremia, such as an increased prevalence of prosthetic devices (e.g., orthopedic implants, artificial valves, and pacemakers) and a greater incidence of surgical site infections 1 month before bacteremia onset. Also, Charles et al. [13] found that patients with hVISA infection had a longer bacteremia clearance time than patients with MRSA infection. The prolonged duration of bacteremia was probably associated with inadequate antimicrobial therapy among patients with hVISA bacteremia, as well as with the presence of prosthetic device infection. There was no correlation between vancomycin blood level and duration of bacteremia. Vancomycin levels were in the recommended range (15 mg/L) for most patients, particularly those with hVISA bacteremia, leading to the conclusion that prolonged bacteremia was not related to inadequate vancomycin levels. This contradicts reports by others [13] .
It is also possible that hVISA isolates have specific biological features that enable them to cause prolonged bacteremia and foreign-body infections. The agr regulatory system has been linked to low-level vancomycin resistance in S. aureus, suggesting that agr type II strains and the loss of agr function are associated with VISA [19] . Loss of agr function could significantly affect the expression of adhesion and could potentially promote biofilm formation. Because VISA infections were shown to involve prosthetic devices, the formation of biofilms on the devices could constitute an important early step in the development of vancomycin resistance [20] .
Rifampin resistance developed mainly among patients with hVISA bacteremia, reflecting the high bacterial load in these infections. Furthermore, because vancomycin and rifampin were coadministered, particularly during the initial days of bacteremia, the only active antibiotic to which these isolates were exposed was rifampin, to which they developed resistance. It has been demonstrated that resistance to rifampin occurs more often when rifampin is given as a sole agent for the treatment of S. aureus infections [21] .
Most published studies on hVISA infections found high mortality and morbidity. However, these findings were mostly from descriptive studies [10 -12] , and in the only comparative study, just 5 patients with hVISA infection were included [13] . Thus, our work is the first comparative study to include 250 patients with 27 hVISA cases, and our findings support previous reports that mortality among patients with hVISA is not greater than mortality among patients with MRSA [13] ; yet, a larger sample might change this finding. Furthermore, it is possible that the contribution of comorbidities to the mortality rate in S. aureus bacteremia is so high that resistance patterns are less conspicuous and require larger samples for their demonstration [18] . All patients in the study received vancomycin as the firstline therapy for MRSA or hVISA bacteremia, but as knowledge about hVISA infections increased during the study, other antibiotics were added to vancomycin treatment, usually late in the course of disease. Therefore, our data do not imply that other antibiotics are superior or inferior to vancomycin in the treatment of hVISA infections. As vancomycin is the first agent used in the vast majority of patients with S. aureus infection, we suggest caution in using vancomycin in patients with hVISA. Because the presence of hVISA affects the clinical approach, we recommend routine screening for this type of resistance.
Although the majority of the patients in both study groups were male, female sex was a predictor of mortality (OR, 1.97). The relationship between sex and MRSA/hVISA-attributed mortality was not demonstrated in other studies [18, 22] . Our study has limitations. Data were gathered retrospectively. Physicians were not blinded to the presence of hVISA infection, which might have affected the intensity of care these patients received and might have diminished some of the differences between patients with hVISA and patients with MRSA. We compared hVISA infections that occurred during 2003-2006 with MRSA bacteremia that occurred during [2003] [2004] . This may also lead to bias, although the approach to MRSA infections did not change in our hospital during this period.
In summary, we found the presence of hVISA to be significantly associated with prolonged bacteremia, osteomyelitis, endocarditis, and development of resistance to rifampin. These complications and outcomes were not related to low trough levels of vancomycin. Infection-attributable mortality for hVISA bacteremia was similar to that for MRSA bacteremia.
